The ophthalmology drugs market covers drugs that are used in the treatment of eye related diseases such as refractive errors, cataracts, glaucoma, conjunctivitis, retinal diseases, and macular degeneration. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax.
The top five companies covered are Novartis AG, F. Hoffmann-La Roche Ltd., Allergan Plc., Valeant Pharmaceuticals Intl Inc., and Bayer AG. Novartis AG Group was the largest company in the ophthalmology drugs market.
The countries covered are USA, China, Germany, Brazil, Japan, UK, Spain, Russia, France, Australia, Italy, India and rest of the world.
The global ophthalmology drugs market was valued around $28 billion in 2017. North America was the largest region in the ophthalmology drugs market in 2017, accounting for around 31% of the total market. The USA was the largest country in the market accounting for around 28% of the total market.
Development of combination therapies for the treatment of eye related diseases including glaucoma is an emerging trend in the ophthalmology drugs market. Combination therapy involves use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of eye drops or drug administration, and reduce the possibility of vascular endothelial growth factor (VEGF) expression, choroidal neovascularization and inflammation.